Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

PHIO PHARMACEUTICALS CORP.

(PHIO)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Investment -
Trading -
ESG Refinitiv -
Financials
Sales Growth
Growth rating is based on the evolution of the turnover of the company between the last year and the three coming years according to consensus estimates
-
Earnings Growth -
EBITDA / Sales -
Profitability
Profitability rating is based on net margin of the company for the current year and the next one according to consensus estimates
-
Finances
Finances rating is based on the evolution of the net debt of the company (debt or cash) and its Ebitda, compared to its revenue
-
Valuation
P/E ratio
Price Earnings Ratio rating compared the companyĺs current share price to its per-share earnings for the current fiscal year and the next one
-
EV / Sales
Valuation rating is based on the ratio between enterprise value and its turnover for the current fiscal year and the next one
-
Price to Book -
Price to Free Cash Flow -
Yield
"Yield" rating is based on the dividend relative to its share price
-
Momentum
Turnover review 12m
Revenue revisions (one year) rating is based on the evolution of revenue revisions of the company for the current fiscal year and the next one
Turnover review 4m
Revenue revisions (four months) rating is based on the evolution of revenue revisions of the company for the current fiscal year and the next one
Turnover review 7 days
Earnings revision 12m
EPS revisions (one year) rating is based on the evolution of EPS (earnings per share) revisions of the company for the current fiscal year and the next one
Earnings revision 4m
EPS revisions (four months) rating is based on the evolution of EPS (earnings per share) revisions of the company for the current fiscal year and the next one
Consensus
Analyst Opinion
Consensus rating is based on analyst recommendations
Potential Price Target
Potential rating is based on the average target price fixed by the consensus from Thomson Reuters
Price target revision 4m
Revision of opinion 4m -
Revision of opinion 12m
Business Predictability
Analyst Coverage
Divergence of Estimates
Business Predictability rating is based on the dispersion of analysts' estimates on the evolution of the company business in the coming years (range estimates)
-
Divergence of analysts' opinions -
Divergence of Target Price
Earnings quality
Earnings quality rating is based on quality of past earnings released by the company compared to analysts' estimates
Technical analysis
Short Term Timing
Short Term Timing rating is defined according to the positioning of the last closed trading price, within the area between the short term support and resistance on the basis of technical analysis in daily data
Middle Term Timing
Mid-Term Timing rating is defined according to the positioning of the last closed trading price, within the area between the mid-term support and resistance on the basis of technical analysis in daily data
Long Term Timing
Long Term Timing rating is defined according to the positioning of the last closed trading price, within the area between the long term support and resistance on the basis of technical analysis in daily data
RSI
RSI rating is based on the ranking of the security in the panel studied according to the mathematical indicator RSI 14 period
Bollinger Spread
Bollinger Bands rating is based on the ranking of the security in the panel studied according to the spread of the Bollinger bands
Unusual Volumes
Abnormal Volumes rating is based on the ranking of the security in the panel studied according to volume of the last session compared to an average session
Strengths
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
  • Consensus analysts have strongly revised their opinion of the company over the past 12 months.
  • Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
Ratings chart - Surperformance
Sector Other Biotechnology & Medical Research
1st jan.Capitalisation (M$)Investor Rating
PHIO PHARMACEUTICALS CORP.-32.71%24
-
MODERNA, INC.301.12%168 260
LONZA GROUP AG26.76%59 023
IQVIA HOLDINGS INC.39.45%47 876
CELLTRION, INC.-25.07%32 166
SEAGEN INC.-6.81%29 694
PHARMARON BEIJING CO., LTD.94.07%26 319
HANGZHOU TIGERMED CONSULTIN..7.30%21 942
ALNYLAM PHARMACEUTICALS, IN..41.14%21 801
CUREVAC N.V.-28.57%21 497
CHARLES RIVER LABORATORIES ..66.62%20 921
ICON PUBLIC LIMITED COMPANY26.20%19 608
BIO-TECHNE CORPORATION53.28%18 931
INCYTE CORPORATION-10.38%17 079
NOVAVAX, INC.100.71%16 580
PPD, INC.34.34%16 150
More Results